Theravance Biopharma Inc (TBPH) Shares Bought by State Board of Administration of Florida Retirement System

Share on StockTwits

State Board of Administration of Florida Retirement System boosted its stake in Theravance Biopharma Inc (NASDAQ:TBPH) by 12.2% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 28,578 shares of the biopharmaceutical company’s stock after buying an additional 3,100 shares during the quarter. State Board of Administration of Florida Retirement System’s holdings in Theravance Biopharma were worth $648,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in the business. Woodford Investment Management Ltd lifted its position in Theravance Biopharma by 1.4% in the 1st quarter. Woodford Investment Management Ltd now owns 10,898,879 shares of the biopharmaceutical company’s stock worth $264,297,000 after buying an additional 151,771 shares in the last quarter. Northern Trust Corp lifted its position in Theravance Biopharma by 0.9% in the 1st quarter. Northern Trust Corp now owns 516,551 shares of the biopharmaceutical company’s stock worth $12,526,000 after buying an additional 4,509 shares in the last quarter. State of New Jersey Common Pension Fund D lifted its position in Theravance Biopharma by 17.7% in the 2nd quarter. State of New Jersey Common Pension Fund D now owns 265,459 shares of the biopharmaceutical company’s stock worth $6,021,000 after buying an additional 40,000 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its position in Theravance Biopharma by 4.7% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 209,075 shares of the biopharmaceutical company’s stock worth $5,071,000 after buying an additional 9,398 shares in the last quarter. Finally, Senzar Asset Management LLC lifted its position in Theravance Biopharma by 9.3% in the 1st quarter. Senzar Asset Management LLC now owns 187,856 shares of the biopharmaceutical company’s stock worth $4,555,000 after buying an additional 16,056 shares in the last quarter. Institutional investors own 85.81% of the company’s stock.

A number of equities research analysts have issued reports on TBPH shares. Cantor Fitzgerald set a $55.00 target price on shares of Theravance Biopharma and gave the stock a “buy” rating in a research report on Tuesday, May 8th. Leerink Swann set a $31.00 price target on shares of Theravance Biopharma and gave the company a “buy” rating in a report on Wednesday, May 9th. Needham & Company LLC restated a “buy” rating and set a $40.00 price target on shares of Theravance Biopharma in a report on Wednesday, May 9th. BidaskClub upgraded shares of Theravance Biopharma from a “sell” rating to a “hold” rating in a report on Friday, May 11th. Finally, ValuEngine downgraded shares of Theravance Biopharma from a “hold” rating to a “sell” rating in a report on Tuesday, May 22nd. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. Theravance Biopharma presently has a consensus rating of “Hold” and an average price target of $40.00.

Theravance Biopharma stock opened at $29.39 on Wednesday. The company has a debt-to-equity ratio of 6.52, a current ratio of 4.14 and a quick ratio of 3.95. Theravance Biopharma Inc has a 1-year low of $21.27 and a 1-year high of $35.90.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings results on Wednesday, August 1st. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.44. The business had revenue of $23.48 million for the quarter, compared to the consensus estimate of $9.97 million. Theravance Biopharma had a negative net margin of 640.07% and a negative return on equity of 261.70%. research analysts forecast that Theravance Biopharma Inc will post -4.41 earnings per share for the current year.

In other news, CFO Renee D. Gala sold 43,743 shares of the firm’s stock in a transaction on Wednesday, August 15th. The shares were sold at an average price of $26.79, for a total transaction of $1,171,874.97. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Bradford J. Shafer sold 7,119 shares of the firm’s stock in a transaction on Monday, August 27th. The shares were sold at an average price of $27.71, for a total transaction of $197,267.49. Following the transaction, the executive vice president now owns 84,000 shares in the company, valued at approximately $2,327,640. The disclosure for this sale can be found here. Insiders have sold a total of 96,202 shares of company stock worth $2,580,203 in the last 90 days. 6.90% of the stock is owned by insiders.

About Theravance Biopharma

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria.

Featured Story: Market Capitalization in the Stock Market

Want to see what other hedge funds are holding TBPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Theravance Biopharma Inc (NASDAQ:TBPH).

Institutional Ownership by Quarter for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply